Spero Therapeutics (NASDAQ:SPRO) Stock: Insider Esther Rajavelu Sells 40,851 Shares

Spero Therapeutics, Inc. (NASDAQ:SPRO) insider Esther Rajavelu sold 40,851 shares of the business’s stock in a transaction dated Monday, November 9th. The shares were sold at an average price of $1.04, for a total value of $42,485.04. Following the completion of the sale, the insider directly owned 946,000 shares of the company’s stock, valued at approximately $983,840. This represents a 4.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Spero Therapeutics Stock Up 1.0%

Shares of NASDAQ SPRO opened at $1.02 on Thursday. The stock’s 50 day moving average price is $1.15 and its two-hundred day moving average price is $1.93. Spero Therapeutics, Inc. has a 52-week low of $0.96 and a 52-week high of $3.08. The stock has a market capitalization of $59.40 million, a P/E ratio of 9.18 and a beta of 1.59.

Spero Therapeutics (NASDAQ:SPRO) last issued its earnings results on Wednesday, August 12th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.01. Spero Therapeutics had a return on equity of 16.17% and a net margin of 24.90%. On average, analysts anticipate that Spero Therapeutics, Inc. will post -0.97 EPS for the current year.

Hedge Funds Weigh In On Spero Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Susquehanna Fundamental Investments LLC bought a new stake in shares of Spero Therapeutics in the 2nd quarter worth approximately $36,000. Global Retirement Partners LLC bought a new position in Spero Therapeutics during the 2nd quarter worth $55,000. GSA Capital Partners LLP bought a new position in Spero Therapeutics during the 2nd quarter worth $632,000. BlackRock Inc. bought a new position in Spero Therapeutics during the 2nd quarter worth $1,314,000. Finally, Alphabet Inc. bought a new position in Spero Therapeutics during the 2nd quarter worth $1,967,000. 25.60% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. Zacks Research upgraded shares of Spero Therapeutics to a “hold” rating in a research note on Monday, September 14th. HC Wainwright raised their price target on shares of Spero Therapeutics from $5.00 to $6.00 and gave the stock a “buy” rating in a research report on Monday, September 14th. Cantor Fitzgerald began coverage on shares of Spero Therapeutics in a research report on Wednesday, October 28th. They issued an “overweight” rating and a $6.00 price target on the stock. Compass Point raised shares of Spero Therapeutics to a “neutral” rating in a report on Monday, September 14th. Finally, Weiss Ratings raised shares of Spero Therapeutics from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday. Two research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $6.00.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc. (NASDAQ:SPRO) is a biopharmaceutical company focused on developing treatments for multidrug-resistant bacterial infections and certain rare diseases. The company’s research programs are designed to address infections for which existing antibiotics may be inadequate, including complicated urinary tract infections and infections caused by difficult-to-treat pathogens. Spero’s lead product candidate has been tebipenem pivoxil hydrobromide, an orally administered carbapenem antibiotic developed for the treatment of complicated urinary tract infections.